Phioanh L. Nghiemphu

Neurology

300 Medical Plz
Los Angeles, CA 90095

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 136 publications

Clinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-mutant gliomas treated with bevacizumab.

Clinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-mutant gliomas treated with bevacizumab.

Journal: Neuro-oncology advances

Published: December 29, 2025

MGMT downregulation by CRISPR/Cas13 RNA-guided RNA targeting enhances glioma cell sensitivity to TMZ chemotherapy.

MGMT downregulation by CRISPR/Cas13 RNA-guided RNA targeting enhances glioma cell sensitivity to TMZ chemotherapy.

Journal: Journal of neuro-oncology

Published: November 01, 2025

A multifocal IDH-mutant glioma with differential response to IDH inhibition: Role of quantitative neuroimaging.

A multifocal IDH-mutant glioma with differential response to IDH inhibition: Role of quantitative neuroimaging.

Journal: Radiology case reports

Published: October 27, 2025

Adult patient and caregiver perspectives on the impact of NF1-PN: Insights from a US qualitative survey.

Adult patient and caregiver perspectives on the impact of NF1-PN: Insights from a US qualitative survey.

Journal: Neuro-oncology advances

Published: September 09, 2025

Perfusion, diffusion, and anatomical MRI characteristics of pathologically confirmed malignant transformation in IDH-mutant gliomas.

Perfusion, diffusion, and anatomical MRI characteristics of pathologically confirmed malignant transformation in IDH-mutant gliomas.

Journal: Neuro-oncology

Published: September 01, 2025

A single-institution retrospective study of multicentric gliomas stratified by IDH mutational status.

A single-institution retrospective study of multicentric gliomas stratified by IDH mutational status.

Journal: Neuro-oncology advances

Published: August 14, 2025

Selumetinib for adults with NF1-associated plexiform neurofibromas: Insights from the KOMET study.

Selumetinib for adults with NF1-associated plexiform neurofibromas: Insights from the KOMET study.

Journal: Neuro-oncology

Published: July 24, 2025

"It's not any one thing, it's always all of them, all at the same time": quality of life in NF2-related schwannomatosis from patient and clinician perspectives.

"It's not any one thing, it's always all of them, all at the same time": quality of life in NF2-related schwannomatosis from patient and clinician perspectives.

Journal: Familial cancer

Published: July 14, 2025

Impact of corticosteroid administration on contrast-enhancing volume and diffusion MRI in treatment naïve glioblastoma.

Impact of corticosteroid administration on contrast-enhancing volume and diffusion MRI in treatment naïve glioblastoma.

Journal: Neuro-oncology

Published: May 30, 2025

Reply to: Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas.

Reply to: Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 19, 2025

A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma.

A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma.

Journal: Neuro-oncology advances

Published: March 07, 2025

Advanced imaging characterization of post-chemoradiation glioblastoma stratified by diffusion MRI phenotypes known to predict favorable anti-VEGF response.

Advanced imaging characterization of post-chemoradiation glioblastoma stratified by diffusion MRI phenotypes known to predict favorable anti-VEGF response.

Journal: Journal of neuro-oncology

Published: February 13, 2025

Showing 1-12 of 136

Last Updated: 09/26/2026